ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1594

High Expression of CD38 on CD8 T Cells Predicts Increased Burden of Infections in Patients with SLE

Lama Mulki1, Abel Suarez-Fueyo 2, Eri Katsuyama 2, Vasileios Kyttaris 2 and George Tsokos 2, 1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biomarkers, Lupus, SLE and infection

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: We have previously reported that CD38 gene expression in the peripheral blood T cell from patients with SLE is increased. CD8+CD38+ T cells have impaired cytotoxicity leading to increased risk of infections. The purpose of the current study was to further investigate whether the expansion of CD8+CD38+ T cells in patients with SLE predicts increased load of infectious episodes.

Methods: CD38 surface expression was measured by flow cytometry in fresh T cells from patients with SLE (n=43) over a period of time ranging from 6 to 24 months. The expression of CD38 on the surface of T cells was estimated my flow cytometry. Clinical parameters (SLEDAI, flare rate and medications) as well as rate and type of infections were recorded from patients with SLE for further analysis.

Results: CD38 surface expression was higher in CD8+ T cells from patients with SLE (30%±3, n=37) compared to normal controls (18.7% 1, n=18, p< 0.001). Within group of patients with SLE we identified two groups of patients: those with high ( > 28.9%; mean +2 standard deviations of normal values) and those with low (< 28.9%) expression levels of CD38. We followed these patients longitudinally and recorded number of infections over the study period. 43 subjects were found to had two or more visits. Interestingly, 23 out of the 30 SLE patients with lower percentage of CD8+CD38+ T cells did not report any infections at the initial visit compared with 4 out of the 14 SLE with higher CD8+CD38+ percentages who reported at least one infectious episode (p< 0.01 using Chi-squared test). Even more, patients with SLE who had a higher percentage of CD8+CD38+ T cells (n=32) at their initial visit were more prone to developing subsequent infections (1.1 infections/year) compared to those with low percentage of CD8+CD38+ cells (n=14, 0.7 infection/year, p=0.05). Early analyses did not reveal an association with disease activity and treatment.

Conclusion: Our data indicate that increased percentage of CD8+CD38+ T cells in the peripheral blood of patients with SLE predicts increased numbers of infections. Identification of this subset of patients should alert care-takers to expect, identify and treat promptly in order to limit morbidity and mortality.


Disclosure: L. Mulki, None; A. Suarez-Fueyo, None; E. Katsuyama, GSK, Horizon Pharma, Exagen Diagnostics; V. Kyttaris, exagen diagnostics, 2, Exagen Diagnostics, 2, GSK, 5, gsk, 5, horizon pharma, 5, Horizon Pharma, 5; G. Tsokos, Janssen Research & Development, LLC, 2.

To cite this abstract in AMA style:

Mulki L, Suarez-Fueyo A, Katsuyama E, Kyttaris V, Tsokos G. High Expression of CD38 on CD8 T Cells Predicts Increased Burden of Infections in Patients with SLE [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/high-expression-of-cd38-on-cd8-t-cells-predicts-increased-burden-of-infections-in-patients-with-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-expression-of-cd38-on-cd8-t-cells-predicts-increased-burden-of-infections-in-patients-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology